Richard Miller Thanks, Leiv, and good afternoon, everyone. Thank you for joining us today for our business update call.As we look into 2025, we remain optimistic on the potential for soquelitinib to provide a powerful new approach for the treatment of a broad range of immune diseases and cancer. Soquelitinib is well-positioned as a first-in-class